세계의 동물용 생물제제 시장 : 제품 유형별, 동물 유형별, 투여 경로별, 용도별, 최종사용자별, 지역별 - 예측(-2030년)

The global veterinary biologics market is projected to reach USD 3.51 billion by 2030 from USD 2.72 billion in 2025, at a CAGR of 5.2% during the forecast period.

The veterinary biologics market is experiencing significant growth, driven by an expanding companion animal population and rising pet ownership. Increasing concerns about chronic diseases have further boosted demand for veterinary treatments. Government and animal welfare organizations actively promote awareness campaigns, encouraging early diagnosis and treatment of dermatological conditions in both pets and farm animals.

Additionally, the growing adoption of pet insurance and high expenditure on animal healthcare support market expansion by improving access to specialized veterinary services. However, the market faces challenges such as the rising cost of pet care, which can limit treatment adoption. Moreover, strict regulatory guidelines and lengthy drug approval processes further restrain market growth.

"The monoclonal antibodies segment has accounted for the largest market share in the veterinary biologics market."

Monoclonal antibodies are projected to experience rapid growth in the veterinary biologics market, driven by their targeted action, high effectiveness, and increasing adoption in livestock health management. These biologics are increasingly used to prevent and treat specific diseases by precisely targeting pathogens or toxins, providing a more selective and effective alternative to traditional therapies like antibiotics. In livestock applications, monoclonal antibodies are especially valuable for conditions that require swift immune support, resulting in decreased morbidity and higher productivity. Their use aligns with the global shift toward sustainable animal farming practices and the reduction of antimicrobial resistance (AMR), making them a preferred choice for advanced biologic treatments.

"The dermatology segment accounted for the largest market share in 2024 in the veterinary biologics market."

The dermatology segment is expected to dominate the veterinary biologics market because of the high prevalence of skin disorders like atopic dermatitis, mange, and flea- or tick-borne skin infections in companion animals. Increasing pet ownership and greater awareness of animal health have boosted demand for advanced dermatological treatments. Biologics, such as monoclonal antibodies, are becoming more popular as effective, targeted therapies with fewer side effects compared to traditional drugs. More approvals of dermatology-focused veterinary biologics, including those targeting chronic skin allergies, further strengthen this segment. Additionally, dermatological issues are among the most common reasons for veterinary visits, ensuring steady demand. Growth in companion animal insurance coverage is also supporting the adoption of high-cost biologics. Overall, these factors position dermatology as the leading segment in the veterinary biologics market.

"North America has accounted for the largest market share in 2024."

North America held the largest market share in 2024, supported by a well-established veterinary healthcare infrastructure and high pet ownership rates. The region has a strong presence of leading market players investing in research and development for innovative monoclonal antibody therapies. Rising awareness about pet health, along with increasing spending on veterinary care, drives market growth. Additionally, the growing demand for premium pet care products further contributes to North America's dominance in the global veterinary monoclonal antibody industry.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-75%, Tier 2-15%, and Tier 3- 10%
• By Designation: C-level-30%, Director-level-23%, and Other Designations-47%
• By Region: North America-35%, Europe-20%, Asia Pacific-25%, Latin America-13%, and Middle East & Africa-7%

The major players operating in the veterinary biologics market are Zoetis (US), Elanco (US), and Merck & Co., Inc. (US).

Research Coverage

This report studies the veterinary biologics market based on animal type, route of administration, product, application, end user, and region. The report also examines factors such as drivers, restraints, opportunities, and challenges that affect market growth. It analyzes the opportunities and challenges within the market and provides details about the competitive landscape for market leaders. Additionally, the report analyzes micro markets in terms of their individual growth trends and forecasts the revenue of market segments across five main regions and their respective countries.

Reasons to Buy the Report

The report can help established firms, as well as new entrants/smaller firms, gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the five strategies mentioned below.

This report provides insights into the following points:

• Analysis of key drivers (Surge in companion animal population and pet ownership. Increasing incidence of infectious zoonotic diseases, Innovations in monoclonal antibodies targeting infectious diseases, Supportive initiatives by government agencies and animal health organization, Growing demand for animal-derived food products), restraints (High cost of veterinary diagnostic tests, Regulatory hurdles and long approval timelines), opportunities (evolving landscape of strategic collaborations and partnerships, untapped growth potential in emerging markets, challenges (Limited Awareness and Shortage of Trained Veterinarians in Low-Income Countries.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the veterinary biologics market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of biologic treatments across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the veterinary biologics market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the veterinary biologics market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key objectives of primary research
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primaries
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
  • 2.2.2 EPIDEMIOLOGY-BASED APPROACH
  • 2.2.3 COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS
  • 2.2.4 TOP-DOWN APPROACH
  • 2.2.5 BOTTOM-UP APPROACH
• 2.3 MARKET GROWTH RATE PROJECTION
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 VETERINARY BIOLOGICS MARKET OVERVIEW
• 4.2 NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE AND COUNTRY
• 4.3 VETERINARY BIOLOGICS MARKET SHARE, BY PRODUCT TYPE, 2025 VS. 2030
• 4.4 VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2025 VS. 2030 (USD MILLION)
• 4.5 VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)
• 4.6 VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
• 4.7 VETERINARY BIOLOGICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Surge in companion animal population and pet ownership
    • 5.2.1.2 Increasing incidence of infectious zoonotic diseases
    • 5.2.1.3 Innovations in monoclonal antibodies targeting infectious diseases
    • 5.2.1.4 Supportive initiatives by government agencies and animal health organizations
    • 5.2.1.5 Rising demand for animal-derived food products
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of veterinary diagnostic tests
    • 5.2.2.2 Regulatory hurdles and long approval timelines
    • 5.2.2.3 Rising pet care costs
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Evolving landscape of strategic collaborations and acquisitions
    • 5.2.3.2 Untapped growth potential in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Limited awareness and shortage of trained veterinarians in low-income countries
    • 5.2.4.2 Stringent regulatory requirements for licensing veterinary biologics
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 KEY TECHNOLOGIES
    • 5.3.1.1 Hybridoma technology
    • 5.3.1.2 Biosensor-based diagnostic systems
  • 5.3.2 COMPLEMENTARY TECHNOLOGIES
    • 5.3.2.1 Long-acting injectables
    • 5.3.2.2 Next-generation sequencing
  • 5.3.3 ADJACENT TECHNOLOGIES
    • 5.3.3.1 Wearable biosensors & remote monitoring devices
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT DATA FOR HS CODE 300214, 2021-2024
  • 5.6.2 EXPORT DATA FOR HS CODE 300214, 2021-2024
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF SUPPLIERS
  • 5.7.4 BARGAINING POWER OF BUYERS
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.8.2 KEY BUYING CRITERIA
• 5.9 REGULATORY ANALYSIS
  • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9.2 REGULATORY FRAMEWORK
    • 5.9.2.1 North America
    • 5.9.2.2 Europe
    • 5.9.2.3 Asia Pacific
    • 5.9.2.4 Latin America
    • 5.9.2.5 Middle East & Africa
• 5.10 PATENT ANALYSIS
  • 5.10.1 PATENT PUBLICATION TREND
  • 5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.10.3 INNOVATIONS AND PATENT REGISTRATIONS
• 5.11 PRICING ANALYSIS
  • 5.11.1 INDICATIVE PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY KEY PLAYER, 2024
  • 5.11.2 INDICATIVE PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY REGION, 2022-2024
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 ECOSYSTEM ANALYSIS
  • 5.13.1 ROLE IN ECOSYSTEM
• 5.14 REIMBURSEMENT ANALYSIS
• 5.15 UNMET NEEDS
• 5.16 IMPACT OF AI/GEN AI ON VETERINARY BIOLOGICS MARKET
  • 5.16.1 POTENTIAL OF AI IN VETERINARY BIOLOGICS
  • 5.16.2 AI USE CASES
  • 5.16.3 KEY COMPANIES IMPLEMENTING AI
• 5.17 INVESTMENT & FUNDING SCENARIO
• 5.18 PIPELINE ANALYSIS
• 5.19 IMPACT OF 2025 US TARIFF ON VETERINARY BIOLOGICS MARKET
  • 5.19.1 INTRODUCTION
  • 5.19.2 KEY TARIFF RATES
  • 5.19.3 PRICE IMPACT ANALYSIS
  • 5.19.4 IMPACT ON COUNTRY/REGION
  • 5.19.5 IMPACT ON END-USE INDUSTRIES
    • 5.19.5.1 Veterinary hospitals & clinics
    • 5.19.5.2 Veterinary diagnostic labs
    • 5.19.5.3 Other end users

6 VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE

• 6.1 INTRODUCTION
• 6.2 MONOCLONAL ANTIBODIES
  • 6.2.1 INCREASED PET OWNERSHIP AND HUMANIZATION TO RAISE HEALTH AWARENESS AND SPENDING ON ANTIBODY THERAPIES
• 6.3 IMMUNOGLOBULINS & ANTITOXINS
  • 6.3.1 INCREASED PREVALENCE OF ZOONOTIC AND TOXIN-MEDIATED DISEASES TO FUEL MARKET GROWTH
• 6.4 IMMUNOMODULATORS & IMMUNOSTIMULANTS
  • 6.4.1 IMMUNOMODULATORS & IMMUNOSTIMULANTS TO CORRECT IMMUNE DYSFUNCTIONS AND CONTROL OVERACTIVE IMMUNE CONDITIONS
• 6.5 DIAGNOSTIC KITS
  • 6.5.1 DIAGNOSTIC KITS TO IMPROVE DISEASE SURVEILLANCE AND MANAGEMENT IN COMPANION ANIMALS, LIVESTOCK, AND POULTRY

7 VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE

• 7.1 INTRODUCTION
• 7.2 COMPANION ANIMALS
  • 7.2.1 CANINE
    • 7.2.1.1 Widespread ownership of pet dogs to generate consistent demand for preventive care and advanced biologics
  • 7.2.2 FELINE
    • 7.2.2.1 Rising pet cat population and increasing feline diseases to propel market growth
• 7.3 LIVESTOCK ANIMALS
  • 7.3.1 BOVINE
    • 7.3.1.1 Need for better herd healthcare and introduction of antibody-based biologics to fuel segment growth
  • 7.3.2 SMALL RUMINANT
    • 7.3.2.1 Increasing global demand for sheep & goat meat and expanding herd size to boost market growth
  • 7.3.3 PORCINE
    • 7.3.3.1 Innovation in monoclonal antibodies for infectious diseases to drive market
  • 7.3.4 POULTRY
    • 7.3.4.1 Rising frequency of poultry diseases to augment market growth for better poultry health and improved food security
  • 7.3.5 EQUINE
    • 7.3.5.1 Equestrian sports, recreational riding, and managing failure of passive transfer (FPT) in foals to drive market

8 VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION

• 8.1 INTRODUCTION
• 8.2 INJECTABLE ROUTE OF ADMINISTRATION
  • 8.2.1 SUBCUTANEOUS ROUTE OF ADMINISTRATION
    • 8.2.1.1 Ease of administration, reduced pain, and lower risk of tissue damage to aid market growth
  • 8.2.2 INTRAMUSCULAR ROUTE OF ADMINISTRATION
    • 8.2.2.1 Better immune response and lower rate of injection-site reactions to fuel market growth
  • 8.2.3 INTRAVENOUS ROUTE OF ADMINISTRATION
    • 8.2.3.1 Rapid action and targeted therapy to drive adoption of intravenous biologics
  • 8.2.4 OTHER INJECTABLE ROUTES OF ADMINISTRATION
• 8.3 ORAL ROUTE OF ADMINISTRATION
  • 8.3.1 EASE OF ADMINISTRATION AND COST-EFFECTIVENESS TO FOCUS ON LARGE-SCALE, NON-INVASIVE ORAL DELIVERY
• 8.4 OTHER ROUTES OF ADMINISTRATION

9 VETERINARY BIOLOGICS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 DERMATOLOGY
  • 9.2.1 PREVALENCE OF CHRONIC SKIN CONDITIONS TO AUGMENT VETERINARY DERMATOLOGY MARKET GROWTH
• 9.3 DIAGNOSTIC TESTING
  • 9.3.1 RISING PREVALENCE OF ZOONOTIC AND VIRAL DISEASES TO INCREASE DEMAND FOR BIOLOGIC-BASED DIAGNOSTIC TOOLS
• 9.4 PAIN MANAGEMENT
  • 9.4.1 NEED FOR NON-OPIOID, SIDE-EFFECT-FREE PAIN SOLUTIONS AMONG PET OWNERS TO DRIVE MARKET
• 9.5 INFECTIOUS DISEASE PREVENTION
  • 9.5.1 RISING INCIDENCE OF ZOONOTIC DISEASES AND ACUTE INFECTIONS TO ACCELERATE USE OF VETERINARY BIOLOGICS
• 9.6 ONCOLOGY
  • 9.6.1 FOCUS ON IMMUNE-TARGETED CONTROL OF AGGRESSIVE CANCEROUS TUMORS TO AID MARKET GROWTH
• 9.7 OTHER APPLICATIONS

10 VETERINARY BIOLOGICS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 VETERINARY HOSPITALS & CLINICS
  • 10.2.1 INCREASE IN VETERINARY SPECIALISTS AND RISE IN PET OWNERSHIP TO PROPEL MARKET GROWTH
• 10.3 VETERINARY DIAGNOSTIC LABS
  • 10.3.1 VETERINARY DIAGNOSTIC LABS TO BECOME ESSENTIAL IN DISEASE DETECTION WITH PREVENTIVE BIOLOGIC INTERVENTIONS
• 10.4 OTHER END USERS

11 VETERINARY BIOLOGICS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US to dominate North American veterinary biologics market during forecast period
  • 11.2.3 CANADA
    • 11.2.3.1 Ongoing developments in veterinary monoclonal antibodies and increasing animal health expenditure to fuel market growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Established veterinary infrastructure and innovation funding to provide favorable environment for biologics adoption
  • 11.3.3 UK
    • 11.3.3.1 Strong regulatory framework and high pet population to boost market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Increase in companion animal health spending by pet owners to propel market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Better availability of pet products through large-scale outlets to augment market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Increased pet population and favorable government regulations to drive market
  • 11.3.7 NETHERLANDS
    • 11.3.7.1 Focus on meat export to positively influence veterinary biologics market
  • 11.3.8 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Growing consumption of animal-derived products to propel market growth
  • 11.4.3 CHINA
    • 11.4.3.1 Large pool of food-producing animals and high companion animal ownership to propel market growth
  • 11.4.4 INDIA
    • 11.4.4.1 Rising demand for dairy products to fuel market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Rise in pet ownership to support increased spending on veterinary care
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Expanding pet care industry and increasing chronic veterinary diseases to drive market
  • 11.4.7 NEW ZEALAND
    • 11.4.7.1 Increased pet ownership and demand for advanced veterinary treatments to drive market
  • 11.4.8 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Large-scale livestock operations and strong veterinary infrastructure to drive market
  • 11.5.3 MEXICO
    • 11.5.3.1 Increasing demand for targeted biologics in livestock and pets to drive market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Kingdom of Saudi Arabia (KSA)
      • 11.6.2.1.1 Technology advancements in veterinary diagnostics to boost demand
    • 11.6.2.2 United Arab Emirates (UAE)
      • 11.6.2.2.1 Favorable government support to drive market
    • 11.6.2.3 Rest of GCC Countries
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY BIOLOGICS MARKET
• 12.3 REVENUE ANALYSIS, 2022-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.4.1 VETERINARY BIOLOGICS MARKET SHARE ANALYSIS
  • 12.4.2 US: VETERINARY BIOLOGICS MARKET SHARE ANALYSIS, 2024
  • 12.4.3 VETERINARY DIAGNOSTICS KITS MARKET SHARE ANALYSIS
  • 12.4.4 US: VETERINARY DIAGNOSTIC KITS MARKET SHARE ANALYSIS, 2024
• 12.5 RANKING OF KEY PLAYERS
  • 12.5.1 VETERINARY BIOLOGICS MARKET RANKING
  • 12.5.2 VETERINARY DIAGNOSTIC KITS MARKET RANKING
• 12.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.6.1 STARS
  • 12.6.2 EMERGING LEADERS
  • 12.6.3 PERVASIVE PLAYERS
  • 12.6.4 PARTICIPANTS
  • 12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.6.5.1 Company footprint
    • 12.6.5.2 Region footprint
    • 12.6.5.3 Product type footprint
    • 12.6.5.4 Animal type footprint
    • 12.6.5.5 Application footprint
• 12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.7.1 PROGRESSIVE COMPANIES
  • 12.7.2 RESPONSIVE COMPANIES
  • 12.7.3 DYNAMIC COMPANIES
  • 12.7.4 STARTING BLOCKS
  • 12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.7.5.1 Detailed list of key startup/SMEs
    • 12.7.5.2 Competitive benchmarking of key startups/SMEs
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPANY VALUATION & FINANCIAL METRICS
  • 12.9.1 FINANCIAL METRICS
  • 12.9.2 COMPANY VALUATION
• 12.10 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT LAUNCHES & APPROVALS
  • 12.10.2 DEALS
  • 12.10.3 EXPANSIONS
  • 12.10.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 ZOETIS SERVICES LLC
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches & approvals
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
      • 13.1.1.3.4 Other developments
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 IDEXX
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 ELANCO
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches
      • 13.1.3.3.2 Deals
      • 13.1.3.3.3 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 MERCK & CO., INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches
      • 13.1.4.3.2 Expansions
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 THERMO FISHER SCIENTIFIC INC.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 MnM view
      • 13.1.5.3.1 Right to win
      • 13.1.5.3.2 Strategic choices
      • 13.1.5.3.3 Weaknesses & competitive threats
  • 13.1.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Deals
      • 13.1.6.3.2 Expansions
  • 13.1.7 NEOGEN CORPORATION
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
  • 13.1.8 BIO-RAD LABORATORIES, INC.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
  • 13.1.9 IMMUCELL CORPORATION
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Other developments
  • 13.1.10 INNOVATIVE DIAGNOSTICS
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 BIONOTE USA INC.
  • 13.2.2 BIOCHEK
  • 13.2.3 PLASVACC USA
  • 13.2.4 NOVAVIVE INC.
  • 13.2.5 MG BIOLOGICS
  • 13.2.6 STALLERGENES GREER
  • 13.2.7 BIOSTONE ANIMAL HEALTH
  • 13.2.8 COLORADO SERUM COMPANY
  • 13.2.9 PADULA SERUMS PTY LTD.
  • 13.2.10 LAKE IMMUNOGENICS
  • 13.2.11 INBIOS INTERNATIONAL, INC.
  • 13.2.12 PRINCETON BIOMEDITECH CORPORATION
  • 13.2.13 TETRACORE, INC.
  • 13.2.14 VMRD, INC.
  • 13.2.15 ANIMAB

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 AVAILABLE CUSTOMIZATIONS
  • 14.3.1 GEOGRAPHIC ANALYSIS
  • 14.3.2 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
  • 14.3.3 COMPANY INFORMATION
  • 14.3.4 PRODUCT ANALYSIS
  • 14.3.5 COUNTRY-LEVEL VOLUME ANALYSIS
  • 14.3.6 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
  • 14.3.7 BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS